Phase 1 Clinical Trial of NIB101
First written in FY2023-Q2. 3 of 7 entries say "Restated". Latest entry: FY2025.
No other company in this theme has enough history to compare yet.
- FY2025RestatedAnnual report
「The Phase 1 clinical trial has been discontinued.」
The discontinuation of NIB101's Phase 1 clinical trial continues to be reported. - FY2024DroppedAnnual report
「The Phase 1 clinical trial has been discontinued.」
The previous position that NIB101's Phase 1 clinical trial was ongoing changed to discontinuation. - FY2024-H1SoftenedAnnual report
「Based on the development progress of our clinical-stage pipelines NIB101, NIB102 and NIB103 and preclinical-stage pipelines NIB104 and NIB105, we have decided to make launching a new Phase 1 clinical trial of NIB103 our highest priority among the development programs we will lead going forward.」
There was no direct description of progress on NIB101's Phase 1 trial. Instead, a new Phase 1 trial of NIB103 was designated the highest priority. NIB101 is positioned for advancement, together with the other proprietary pipelines, through approaches including co-development. - FY2024-Q1RestatedAnnual report
「In our proprietary drug discovery business, a Phase 1 clinical trial of our NIB101 pipeline is ongoing, and we are identifying eligible cases.」
The Phase 1 trial of NIB101 and identification of eligible cases continue. - FY2023RestatedAnnual report
「We are currently conducting a Phase 1 clinical trial. The trial summary published by the trial sponsor is as follows.」
The Phase 1 clinical trial of NIB101 remains ongoing. Approximately 42 subjects were disclosed for the dose-escalation and expansion-cohort stages, with the trial scheduled to run from January 2022 through February 2028. Delays caused by manufacturing issues also continue. - FY2023-Q3AdvancedAnnual report
「In our proprietary drug discovery business, we are conducting a Phase 1 clinical trial of our NIB101 pipeline and proceeding with the enrollment of eligible subjects.」
The description progressed from identifying eligible cases to enrolling eligible subjects in the Phase 1 trial. A separate disclosure also reported a substantial delay caused by multiple manufacturing factors. - FY2023-Q2First statedAnnual report
「In our proprietary drug discovery business, a Phase 1 clinical trial of our NIB101 pipeline is ongoing, and we are identifying eligible cases.」
The Phase 1 clinical trial of NIB101 is progressing, with eligible cases being identified.